Medelinked is the First Application to Feature in BioClinica’s App xChange
News Sep 16, 2015
Medelinked has announced that it will be the first application featured in the BioClinica®, eHealth App xChange™, an alliance channel for disruptive technology innovation across life sciences and healthcare.
Medelinked allows individuals to use mobile technology and the cloud to increase the effectiveness of health care by enabling them to securely build their health profile online and to connect and share with their network of trusted health partners.
Pennsylvania -based BioClinica, a global specialty clinical trials technology and services provider that serves more than 400 pharmaceutical, biotechnology, and device organizations, recently launched the eHealth App xChange. It provides healthcare payers, providers, researchers, regulators and patients with access to transformative applications integrated with and delivered through BioClinica’s eHealth Cloud™.
Leading innovation in regulated clinical trials
BioClinica eClinical President, Mukhtar Ahmed says: "Our App xChange is an incubator and growth engine for niche technology providers and individual app developers, so we welcome Medelinked as the first in a series of new partners as BioClinica continues to lead industry innovation within the regulated clinical trial space."
Ahmed continues: "Medelinked’s presence in the App xChange will enable research communities to ensure unique levels of patient and consumer engagement so accelerating pre- and post-approval research while creating efficiency and quality benefits."
Driving the global shift in how patients and the healthcare industry connect
Ian Gallifant, Medelinked founder and CEO, says: “With this latest development, Medelinked is further driving the global shift in how patients and the healthcare industry connect from early clinical research and trials right through to day-to-day health management. The fact that BioClinica has chosen Medelinked to be the first to feature on its new strategic and disruptive platform is a profound endorsement of the quality and effectiveness of Medelinked’s technology.”
A form of the hallucinogenic party drug ketamine has cleared one of the final hurdles toward clinical use as an antidepressant. During a meeting at the US Food and Drug Administration (FDA) in Silver Spring, Maryland, an independent advisory panel voted 14-2 in favor of recommending a compound known as esketamine for use in treating depression.READ MORE